Multiple Myeloma Hub
Episodes
Overview of BCMA-directed therapies for multiple myeloma
24 Apr 2026
Contributed by Lukas
On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life ...
Quality-of-life considerations with BCMA‑directed therapies for MM
23 Apr 2026
Contributed by Lukas
On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of ...
Symposium | Practical considerations when sequencing novel agents and managing AEs with BCMA-directed therapies
12 Feb 2026
Contributed by Lukas
On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel BCMA-directed therapies into clinical practice: Insi...
Symposium | Future directions with novel and established BCMA-DT in the MM treatment paradigm
11 Feb 2026
Contributed by Lukas
On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel BCMA-directed therapies into clinical practice: Insi...
Symposium | Real-world insights and clinical experience with BCMA‑directed therapies
10 Feb 2026
Contributed by Lukas
On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel B-cell maturation antigen (BCMA)-directed therapies ...
Symposium | BCMA-directed therapies in MM: Current applications and the evolving clinical landscape
06 Feb 2026
Contributed by Lukas
On December 17, 2025, the Multiple Myeloma Hub held a virtual symposium, titled Integrating novel B-cell maturation antigen (BCMA)-directed therapies ...
What are the latest updates from the phase I trial of P-BCMA-ALLO1 for the treatment of RRMM?
20 Jan 2026
Contributed by Lukas
The Multiple Myeloma Hub spoke with Mehmet Hakan Kocoglu, University of Maryland, Baltimore, US. We asked, What are the latest updates from the phase ...
Improving access to CAR T-cell therapy for eligible patients with MM
06 Jan 2026
Contributed by Lukas
During the Multiple Myeloma Hub Steering Committee Meeting in November 2025, key opinion leaders met to discuss improving access to chimeric antigen r...
ASH 2025 | CARTITUDE-4: Long-term PFS outcomes with cilta-cel for standard-risk RRMM
11 Dec 2025
Contributed by Lukas
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, December 6–9, 2025, Orlando, US, the Multiple Myeloma Hub was pl...
Clinical experience with belantamab mafodotin: Management strategies for ocular toxicity
23 Oct 2025
Contributed by Lukas
The Multiple Myeloma Hub spoke with Rakesh Popat, University College Hospital, London, UK. We asked about clinical experience with belantamab mafodoti...
MIDAS: MRD-driven strategy after Isa-KRd induction in ND ASCT-eligible MM
22 Oct 2025
Contributed by Lukas
The Multiple Myeloma Hub spoke with Paul Richardson, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, Massachusetts, US. W...
How might the clinical development of CELMoDs impact the treatment paradigm for MM?
20 Oct 2025
Contributed by Lukas
The Multiple Myeloma Hub spoke with Paul Richardson, Dana-Farber Cancer Institute, Boston, US. We asked, How might the clinical development of cereblo...
CARTITUDE-2: Cilta-cel ± Len maintenance for MM with suboptimal response to ASCT
03 Oct 2025
Contributed by Lukas
The Multiple Myeloma Hub spoke with María-Victoria Mateos, University Hospital of Salamanca, ES. We asked about the latest findings from the updated ...
Evolving diagnostic criteria for high-risk smoldering MM
30 Sep 2025
Contributed by Lukas
The Multiple Myeloma Hub spoke with María-Victoria Mateos, University Hospital of Salamanca, Salamanca, Spain. We asked about the evolving diagnostic...
What combination regimens including BiTEs are being evaluated for the treatment of RRMM?
17 Sep 2025
Contributed by Lukas
The Multiple Myeloma Hub spoke with Ravi Vij, Washington University, St. Louis, US. We asked, What combination regimens including bispecific T-cell en...
Risk stratification and prognosis in smoldering MM
10 Sep 2025
Contributed by Lukas
The Multiple Myeloma Hub spoke to Irene Ghobrial, Dana-Farber Cancer Institute, Boston, US. We asked about risk stratification and prognosis in smolde...
What combination regimens containing BCMA-directed bispecific antibodies are being evaluated for MM?
09 Sep 2025
Contributed by Lukas
The Multiple Myeloma Hub spoke with Alexander Lesokhin, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What combination regimens cont...
How can neurotoxicity associated with CAR T-cell therapy in MM be managed?
26 Aug 2025
Contributed by Lukas
The Multiple Myeloma Hub spoke with Peter Forsberg, Colorado Blood Cancer Institute, Denver, US. We asked, How can neurotoxicity associated with chime...
What might be the future applications for BCMA-directed bispecific antibodies in MM and other PCD?
18 Aug 2025
Contributed by Lukas
The Multiple Myeloma Hub spoke with Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US. We asked, What might be the future applic...
What is the rationale for early intervention in high-risk smoldering MM?
30 Jun 2025
Contributed by Lukas
The Multiple Myeloma Hub spoke with Shaji Kumar, Mayo Clinic, Rochester, US. We asked about the future perspectives for the treatment of patients with...
How are BCMA-directed bispecific antibodies currently utilized in real-world practice for MM?
17 Jun 2025
Contributed by Lukas
The Multiple Myeloma Hub was pleased to speak with Hang Quach, St Vincent’s Hospital Melbourne and University of Melbourne, Melbourne, AU. We asked,...
MRD in MM: Implications for clinical practice and trial design
16 Jun 2025
Contributed by Lukas
During the Multiple Myeloma Hub Steering Committee Meeting in April 2025, key opinion leaders met to discuss the implications of measurable residual d...
Targeting XPO1 for the treatment of MM: Real-world evidence
09 Jun 2025
Contributed by Lukas
During the Multiple Myeloma Hub Steering Committee Meeting in April 2025, key opinion leaders met to discuss exportin 1 (XPO1) as a target for the tre...
How to incorporate novel therapies into the treatment paradigm for early RRMM?
30 May 2025
Contributed by Lukas
This educational resource is independently supported by GSK. All content was developed by SES in collaboration with an expert steering committee. Fund...
What are the future perspectives for anti-CD38 mAbs in the treatment of MM?
19 May 2025
Contributed by Lukas
In this interview, Hermann Einsele discusses the future perspectives of anti-CD38 antibodies, highlighting their role in first-line treatment for both...
What are the current treatment recommendations and unmet needs in early RRMM?
13 May 2025
Contributed by Lukas
This educational resource is independently supported by GSK. All content was developed by SES in collaboration with an expert steering committee. Fund...
What is the rationale for treating early RRRM with targeted therapies?
02 May 2025
Contributed by Lukas
The Multiple Myeloma Hub spoke to Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US. We asked, What is the rationale for treatin...
What is the impact of belantamab mafodotin on QoL in patients with MM?
30 Apr 2025
Contributed by Lukas
The Multiple Myeloma Hub spoke to Vania Tietsche de Moraes Hungria, Clínica São Germano, São Paolo, BR. We asked, What is the impact of belantamab ...
What is the impact of elranatamab on quality of life in relapsed/refractory multiple myeloma?
29 Apr 2025
Contributed by Lukas
The Multiple Myeloma Hub spoke with Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR. We asked, What is the impact of elranata...
Symposium | The next wave of immune-based therapies: What you need to know in relapsed/refractory multiple myeloma
13 Aug 2024
Contributed by Lukas
During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite symposium enti...
Integrating cilta-cel into earlier lines of therapy: Rationale and latest data from CARTITUDE-2 and CARTITUDE-4
09 Aug 2024
Contributed by Lukas
Ciltacabtagene autoleucel (cilta-cel) is a B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) T-cell therapy, which is one of ...
Symposium | How to sequence CAR T-cell therapy and bispecific antibodies in relapsed/refractory multiple myeloma
09 Aug 2024
Contributed by Lukas
During the European Hematology Association (EHA) 2024 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint satellite symposium enti...
Teclistamab: real-world safety and efficacy
08 Aug 2024
Contributed by Lukas
During the 65th American Society of Hematology Annual Meeting and Exposition, Dima presented results from a retrospective analysis to evaluate the rea...
Infections associated with bispecific antibodies
16 Jul 2024
Contributed by Lukas
During the Multiple Myeloma Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss key considerations regarding infections ass...
CAR T-cell therapies in clinical practice
16 Jul 2024
Contributed by Lukas
During the Multiple Myeloma Hub Steering Committee Meeting in May 2024, key opinion leaders met to discuss the current use of CAR T-cell therapies in ...
How to select maintenance therapies post-ASCT for patients with high-risk MM?
18 Sep 2023
Contributed by Lukas
The Multiple Myeloma Hub was pleased to speak to Shaji Kumar, Mayo Clinic, Rochester, US, and Naresh Bumma, The Ohio State University, Columbus, US. W...
Should risk-adapted MM treatment be informed by age or frailty status?
12 Sep 2023
Contributed by Lukas
The Multiple Myeloma Hub was pleased to speak to Hira Mian, McMaster University, Hamilton, CA. We asked, Should risk-adapted MM treatment be informed ...
How is the immune reconstitution in patients who stop therapy after achieving MRD negativity?
09 Feb 2023
Contributed by Lukas
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Timothy Schmidt, ...
What are the main discrepancies between MM treating centers in Brazil?
06 Feb 2023
Contributed by Lukas
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Vania Tietsche de...
What are the initial data of dara-CyBorD in patients with extramedullary disease?
03 Feb 2023
Contributed by Lukas
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Meral Beksac, Ank...
Which patients might benefit the most from isatuximab-based combinations in the relapsed setting?
02 Oct 2022
Contributed by Lukas
During the 19th International Myeloma Society Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Roman Hájek, University of Ostrava, Os...
Integrating BCMA-directed agents in the treatment landscape for relapsed/refractory MM
05 Aug 2022
Contributed by Lukas
During a meeting of the Multiple Myeloma Hub Steering Committee on April 26, 2022, María‑Victoria Mateos chaired a recorded discussion that also fe...
The role of consolidation after autologous stem cell transplantation
05 Aug 2022
Contributed by Lukas
During a meeting of the Multiple Myeloma Hub Steering Committee on April 26, 2022, Morie Gertz chaired a recorded discussion that also featu...
What are the pros and cons of bispecific antibodies for multiple myeloma?
25 Jul 2022
Contributed by Lukas
During the ASCO 2022 Congress, the Multiple Myeloma Hub was pleased to speak to Roberto Mina, University of Turin, Turin, IT, and Andrzej J. Jakubowia...
Combining bispecific antibodies with monoclonal antibodies to treat relapsed/refractory MM
21 Apr 2022
Contributed by Lukas
During the 3rd European Myeloma Network Meeting, the Multiple Myeloma Hub was pleased to speak with María-Victoria Mateos, University Hospital of Sal...
Daratumumab as maintenance therapy for transplant-eligible patients with NDMM: What have we learned from GRIFFIN and CASSIOPEIA trials?
14 Jan 2022
Contributed by Lukas
During the 63rd ASH Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Jacob Laubach, Dana-Farber Cancer Institute, Bosto...
Managing infections with novel immunotherapies: Prevention, treatment, and impact on the QoL of patients with MM
09 Nov 2021
Contributed by Lukas
During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Michel Delforge, UCLouvain, Louvain-...
Should 'cure' be the goal for multiple myeloma?
14 Oct 2021
Contributed by Lukas
During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure...
Treating elderly and frail patients with MM: Cure versus disease control
07 Oct 2021
Contributed by Lukas
During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure...
Is transplantation still relevant? If yes, in what context?
30 Sep 2021
Contributed by Lukas
During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure...
The challenges of monitoring organ response in AL amyloidosis: What has been achieved so far?
24 Sep 2021
Contributed by Lukas
During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Eli Muchtar, Mayo Clinic, Rochester, US and Suzanne Lentzsch, Colu...
Is the treatment of high-risk SMM the way for achieving the cure?
23 Sep 2021
Contributed by Lukas
During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure...
Does 'cure' have a different meaning in MM?
15 Sep 2021
Contributed by Lukas
During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure...
How to treat first relapse in lenalidomide-refractory MM?
19 Jul 2021
Contributed by Lukas
During the 2021 ASCO Annual Meeting, the Multiple Myeloma Hub spoke with Clifton C. Mo and Omar Nadeem, Dana-Farber Cancer Institute, Boston, US. We a...
With the unprecedented results seen with novel therapies, what is needed to overcome the poor prognosis of high-risk MM?
30 Jun 2021
Contributed by Lukas
During the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Pieter Sonneveld, Erasmus MC, Rotterdam, NL. We asked, With the unprecedented...
When BCMA-directed therapy is not an option, how should we treat late relapse?
24 May 2021
Contributed by Lukas
During the European School of Haematology (ESH) 3rd How to Diagnose and Treat Multiple Myeloma conference, the Multiple Myeloma Hub spoke to Xavier Le...
What do you need to remember when facing CAR T-cell toxicities?
12 Apr 2021
Contributed by Lukas
During the 3rd European CAR T-cell Meeting, the Multiple Myeloma Hub spoke to Professor Philip McCarthy, Roswell Park Comprehensive Cancer Center, Buf...
What are the key additions to the new NCCN guidelines for multiple myeloma?
07 Apr 2021
Contributed by Lukas
During the National Comprehensive Cancer Network (NCCN) 2021 Annual Conference, the Multiple Myeloma Hub spoke to Natalie S. Callander, University of ...
If maintenance after induction reduces therapy options at relapse, is it still worth it?
01 Apr 2021
Contributed by Lukas
During the 2nd European Myeloma Network Meeting, the Multiple Myeloma Hub spoke to Professor Graham Jackson, Newcastle University, Newcastle upon Tyne...
New findings on the role of the immune microenvironment presented at ASH 2020
16 Feb 2021
Contributed by Lukas
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Elisabet E. Manasanch, MD Anders...
ASH 2020 discussion: Looking for the best partner for lenalidomide maintenance after auto-SCT
09 Feb 2021
Contributed by Lukas
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Francesca Gay (University of Tur...
Should we still use high-dose melphalan in the era of novel agents?
09 Feb 2021
Contributed by Lukas
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Nikhil C. Munshi, Dana-Farber Ca...
What are the unmet needs in AL amyloidosis in Europe?
01 Feb 2021
Contributed by Lukas
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Efstathios Kastritis, Natio...
ASH 2020 discussion: The role of upfront transplant consolidation in the era of novel agents
27 Jan 2021
Contributed by Lukas
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Marc Braunstein, NYU Langone Hea...
Can single cell sequencing help to better define and monitor MM?
17 Dec 2020
Contributed by Lukas
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Maximilian Merz, Heidelberg Univ...
My experience with novel immunotherapies
11 Nov 2020
Contributed by Lukas
During the European School of Haematology (ESH) 5th Translational Research E-Conference on Multiple Myeloma, the Multiple Myeloma Hub was pleased to s...
How can we use the microbiome to improve cancer immunotherapy and alleviate side effect such as graft-versus-host-disease
08 Jul 2020
Contributed by Lukas
During the American Association of Cancer Research (AACR) Virtual Annual Meeting I, the MM Hub was pleased to speak to Christine Spencer, Parker Insti...
Melphalan flufenamide (melflufen) + novel agents for RRMM
08 Jul 2020
Contributed by Lukas
During COMy 2020, Multiple Myeloma Hub Steering Committee Member Paul Richardson, Dana-Farber Cancer Institute, Boston, US, spoke to the Multiple Myel...
Isatuximab plus KRd for high-risk NDMM
24 Jun 2020
Contributed by Lukas
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Katja Weisel, University Canc...
Novel approaches in multiple myeloma: what is unique about CELMoDs?
24 Jun 2020
Contributed by Lukas
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was delighted to speak to Paul Richardson, Dana-Farbe...
Hot topics in MM: quadruplets and anti-BCMA therapy
24 Jun 2020
Contributed by Lukas
During the 25th Congress of the European Hematology Association (EHA), the Multiple Myeloma Hub was pleased to speak to Saad Usmani, Levine Cancer Ins...
Genomics of high-risk myeloma
23 Jun 2020
Contributed by Lukas
During COMy 2020, Nikhil Munshi, Dana-Farber Cancer Institute, Boston, US, spoke to the Multiple Myeloma Hub about genomics of high-risk MM.Here, Nikh...
The association between the diversity of the oral microbiome and PFS
22 Jun 2020
Contributed by Lukas
During the 25th Congress of the European Hematology Association (EHA), the Multiple Myeloma Hub spoke to Steering Committee Member Heinz Ludwig, Wilhe...
Novel approaches in multiple myeloma: BFCR4350A
18 Jun 2020
Contributed by Lukas
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myleoma Hub was pleased to speak to Adam Cohen, University of Pen...
Updates from the KarMMa trial
18 Jun 2020
Contributed by Lukas
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Nikhil Munshi, Dana-Farber Ca...
Update from CARTITUDE-1 | What's new since ASH?
08 Jun 2020
Contributed by Lukas
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Jesus Berdeja, Sarah Cannon R...
Novel approaches in multiple myeloma: TAK-079
04 Jun 2020
Contributed by Lukas
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Amrita Krishnan, City of Hope...
Should we use KRd or VRd for patients with NDMM?
04 Jun 2020
Contributed by Lukas
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was delighted to speak to Shaji Kumar, Mayo Clinic, R...
What is the optimal treatment for bone lesions, including patients with renal insufficiency?
03 Jun 2020
Contributed by Lukas
During the American Society of Clinical Oncology (ASCO) Annual Meeting, the Multiple Myeloma Hub was delighted to speak to Elizabeth O'Donnell, Massac...
Recent advances in our understanding of myeloma progression
02 Jun 2020
Contributed by Lukas
During COMy 2020, Multiple Myeloma (MM) Hub steering committee member, Irene Ghobrial, Dana-Farber Cancer Institute, Boston, US, spoke to the MM Hub a...
Quadruplet combinations in transplant-ineligible NDMM: isatuximab + Vd + cyclo or len
01 Jun 2020
Contributed by Lukas
During the American Society of Clinical Oncology (ASCO) 2020 Meeting, the Multiple Myeloma Hub was pleased to speak to Enrique M. Ocio, Marqués de Va...
How I treat elderly patients with NDMM
28 May 2020
Contributed by Lukas
During COMy 2020, Paula Rodriguez Otero, Clínica Universidad de Navarra, Pamplona, ES, spoke to the Multiple Myeloma (MM) Hub. We asked: How should w...
Understanding resistance mechanisms to current standard of care and how to overcome them
19 May 2020
Contributed by Lukas
During COMy 2020, Enrique Ocio, Marqués de Valdecilla University Hospital, Santander, ES, spoke to the Multiple Myeloma (MM) Hub about resistance mec...
What is plasma cell leukemia and what are the latest advances in treatment?
15 May 2020
Contributed by Lukas
During COMy 2020, Artur Jurczyszyn, Jagiellonian University Medical College, Krakow, PL, spoke to the Multiple Myeloma Hub. We asked: What is plasma c...